CLAIMS

1. A stable pharmaceutical composition comprising an anti-human TSLP receptor antibody, a pharmaceutically acceptable buffer of phosphoric acid in a concentration of 5 to 100 mmol/L; arginine or a pharmaceutically acceptable salt thereof, the concentration of the arginine or the pharmaceutically acceptable salt thereof being 700 mmol/L or less; and
a surfactant, being one, or two or more selected from the group consisting of polysorbates and poloxamer 188, whereby a content of the surfactant is 0.001 to 1% (w/v);

wherein the following (1) and/or (2) is contained as the anti-human TSLP receptor antibody:

(1) an anti-human TSLP receptor antibody comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 1, and a light chain consisting of the amino acid sequence of SEQ ID NO: 3, and

(2) an anti-human TSLP receptor antibody consisting of amino acid sequences of an antibody generated by a post-translational modification of the anti-human TSLP receptor antibody of (1); and

wherein the post-translational modification includes pyroglutamylation at the N-terminus of a heavy chain variable region and/or lysine deletion at the C-terminus of a heavy chain.

2. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is a liquid preparation, or a lyophilized preparation or a spray-dried preparation.

3. The pharmaceutical composition according to claim 2, wherein the pharmaceutical composition is a liquid preparation.

4. The pharmaceutical composition according to claim 2, wherein when the pharmaceutical composition is a liquid preparation, a pH of the liquid preparation is 5 to 6, or

when the pharmaceutical composition is a lyophilized preparation or a spray-dried preparation, a pH of a solution after reconstituting the preparation in water is 5 to 6.

5. The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition is a liquid preparation, and the pH of the liquid preparation is 5 to 6.

6. The pharmaceutical composition according to any one of claims 1 to 5, wherein the surfactant is polysorbate 80.

7. The pharmaceutical composition according to any one of claims 1 to 6, wherein the content of the surfactant is 0.01 to 0.2% (w/v).

8. The pharmaceutical composition according to any one of claims 2 to 7, wherein when the pharmaceutical composition is a liquid preparation, a content of the anti-human TSLP receptor antibody is 0.007 to 2 mmol/L, or when the pharmaceutical composition is a lyophilized preparation or a spray-dried preparation, a content of a solution after reconstituting the preparation in water is 0.007 to 2 mmol/L.

9. The pharmaceutical composition according to any one of claims 1 to 8, when the pharmaceutical composition is stored, each content of a degradant and a multimer is 10% or less, or a content of a chemically modified substance is 50% or less.

10. The pharmaceutical composition according to claim 1, comprising an anti-human TSLP receptor antibody comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 1, and a light chain consisting of the amino acid sequence of SEQ ID NO: 3.

11. The pharmaceutical composition according to claim 1, comprising an anti-human TSLP receptor antibody

consisting of amino acid sequences of an antibody generated by a post-translational modification of an anti-human TSLP receptor antibody comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 1, and a light chain consisting of the amino acid sequence of SEQ ID NO: 3.

12. The pharmaceutical composition according to claim 1, comprising an anti-human TSLP receptor antibody comprising a heavy chain consisting of the amino acid sequence of amino acids 1-447 of SEQ ID NO: 1, and a light chain consisting of the amino acid sequence of SEQ ID NO: 3.

13. The pharmaceutical composition according to claim 1, comprising an anti-human TSLP receptor antibody comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 1, and a light chain consisting of the amino acid sequence of SEQ ID NO: 3, and an anti-human TSLP receptor antibody comprising a heavy chain consisting of the amino acid sequence of amino acids 1-447 of SEQ ID NO: 1, and a light chain consisting of the amino acid sequence of SEQ ID NO: 3.

14. The pharmaceutical composition according to any one of claims 2 to 13, wherein formulation is liquid formulation comprising 0.2mmol/L(30mg/mL) anti-human TSLP receptor antibody, 20mmol/L phosphoric acid, 140 mmol/L L-Arginine Hydrochloride, and 0.02%(w/v) polysorbate 80.